Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 39

Sort by

Sort Order Select

Journal Articles

Anti-Phospholipid Syndrome (APS) Antibody (Ab)-Induced Thrombosis Can be Blocked By Platelet Factor 4 (PF4)-Directed Abs: A Novel Therapeutic Approach for APS?

Amrita Sarkar, Santosh K Yadav, Conroy O Field, Kandace Gollomp, Keith R. McCrae, Thomas L. Ortel, Yves Gruel, Jérôme Rollin, Gowthami M Arepally, Lubica Rauova, Douglas B. Cines, Mortimer Poncz

Blood (2024) 144 (Supplement 1): 2611.

https://doi.org/10.1182/blood-2024-200849

Published: 2024

Journal Articles

Heparin-PEAR1 Interaction Contributes to Platelet Activation By HIT Antibodies

Richard John Buka, Eleyna Martin, Rachel E Lamerton, Hugo Lagonotte, Jérôme Rollin, Yves Gruel, Anthony Calvert, Anthony Poles, Stephen P Watson, Phillip LR Nicolson, Samantha J Montague

Blood (2024) 144 (Supplement 1): 5410.

https://doi.org/10.1182/blood-2024-200026

Published: 2024

Journal Articles

ABO O blood group as a risk factor for platelet reactivity in heparin-induced thrombocytopenia

Blood (2022) 140 (3): 274–284.

https://doi.org/10.1182/blood.2021014240

Published: 2022

Includes: Supplemental data

Journal Articles

The Deglycosylated Form of 1E12, a Monoclonal Anti-PF4 IgG, Strongly Inhibits Antibody-Triggered Cellular Activation in Vaccine-Induced Thrombotic Thrombocytopenia, and Is a Potential New Treatment for Vιττ

Caroline Vayne, Raghavendra Palankar, Sandra Billy, Stefan Handtke, Thomas Thiele, Claire Pouplard, Andreas Greinacher, Yves Gruel, Jérôme Rollin

Blood (2021) 138 (Supplement 1): 582.

https://doi.org/10.1182/blood-2021-147922

Published: 2021

Journal Articles

Genome-Wide Association Study Identifies Variation in ABO As Risk Factor for Platelet Reactivity in Heparin-Induced Thrombocytopenia

Jason B Giles, Jérôme Rollin, PhD, Christian M Shaffer, Heidi E Steiner, Yukihide Momozawa, DVM,PhD, Ian Stanaway, PhD, Taisei Mushiroda, Claire Pouplard, PharmD, PhD, Nancy Heddle, MSc, Michiaki Kubo, MDPhD, Elizabeth Phillips, MD, Theodore E. Warkentin, MD, Yves Gruel, MD PhD, Andreas Greinacher, MD, Dan Roden, MD, Jason Karnes, PhDPharmD

Blood (2020) 136 (Supplement 1): 38–39.

https://doi.org/10.1182/blood-2020-139651

Published: 2020

Journal Articles

Cleavage of anti-PF4/heparin IgG by a bacterial protease and potential benefit in heparin-induced thrombocytopenia

Claire Kizlik-Masson, Quentin Deveuve, Yuhang Zhou, Caroline Vayne, Gilles Thibault, Steven E. McKenzie, Claire Pouplard, Stéphane Loyau, Yves Gruel, Jérôme Rollin

Blood (2019) 133 (22): 2427–2435.

https://doi.org/10.1182/blood.2019000437

Published: 2019

Includes: Supplemental data

Journal Articles

Fibronectin: a “double hit” modulator in HIT?

Yves Gruel, Jerome Rollin

Blood (2019) 133 (9): 891–892.

https://doi.org/10.1182/blood-2019-01-894295

Published: 2019

Journal Articles

Is There an Alternative to Serotonin Release Assay for the Diagnosis of Heparin Induced Thrombocytopenia (HIT)? Evaluation of 5 Other Functional Methods Using 5B9 a Monoclonal IgG That Mimics HIT Human Antibodies

Eve-Anne Guéry, PharmD, Caroline Vayne, PharmD, Cloé Derray, Joévin Besombes, Wayne Corentin Lambert, Jérôme Rollin, PhD, Yves Gruel, MD PhD, Claire Pouplard, PharmD, PhD

Blood (2018) 132 (Supplement 1): 3742.

https://doi.org/10.1182/blood-2018-99-115011

Published: 2018

Journal Articles

Cleavage of Anti-PF4/H IgG Antibodies By Ides, and Potential Benefit in the Treatment of Heparin-Induced Thrombocytopenia

Claire Kizlik-Masson, Quentin Deveuve, Yuhang Zhou, MD PhD, Caroline Vayne, PharmD, Gilles Thibault, PharmD, PhD, Steven Edward McKenzie, MD PhD, Claire Pouplard, PharmD, PhD, Stéphane Loyau, Jérôme Rollin, PhD, Yves Gruel, MD PhD

Blood (2018) 132 (Supplement 1): 518.

https://doi.org/10.1182/blood-2018-99-114450

Published: 2018

Journal Articles

Frequency of Anti-PF4/Heparin Antibodies in Patients Treated with Extra-Corporeal Membrane Oxygenation and Detection By Sensitized Serotonin Release Assay of Pathogenic Heparin-Induced Thrombocytopenia Antibodies

Caroline Vayne, PharmD, Marc-Antoine May, MD, Thierry Bourguignon, MD PhD, Eric Lemoine, MD, Eve-Anne Guéry, PharmD, Jérôme Rollin, PhD, Yves Gruel, MD PhD, Claire Pouplard, PharmD, PhD

Blood (2018) 132 (Supplement 1): 1143.

https://doi.org/10.1182/blood-2018-99-114571

Published: 2018

Journal Articles

Gastrointestinal Bleeding and Angiodysplasia in Von Willebrand Disease: Results from the Ongoing French HRQoL Study: Wish-Qol

Annie Borel-Derlon, MD PhD, Dominique Desprez, MD, Fabienne Volot, MD, Herve Chambost, MD PhD, Sophie Bayard, MD, Catherine Chatelanaz, Catherine Doriat-Robin, Yves Gruel, MD PhD, Agnès Veyradier, Sr., MD PhD, Jenny Goudemand, MD PhD, Sylvia Von Mackensen, PhD

Blood (2017) 130 (Supplement 1): 4866.

https://doi.org/10.1182/blood.V130.Suppl_1.4866.4866

Published: 2017

Journal Articles

Inhibitor Development in Previously Untreated Patients with Severe Hemophilia a Treated with Nuwiq ® , a New Generation Recombinant FVIII of Human Origin

Blood (2016) 128 (22): 327.

https://doi.org/10.1182/blood.V128.22.327.327

Published: 2016

Journal Articles

Characterization of 5B9, a Chimeric Monoclonal Anti-PF4/H Antibody with a Human Fc Fragment and Which Mimics the Effects of HIT Human Antibodies

Jérome Rollin, PhD, Claire Kizlik-Masson, Steven McKenzie, MD PhD, Anne Poupon, PhD, Yuhang Zhou, MD, Caroline Vayne, Gaël Champier, PhD, Claire Pouplard, Pharm D, PhD, Yves Gruel, MD

Blood (2016) 128 (22): 138.

https://doi.org/10.1182/blood.V128.22.138.138

Published: 2016

Journal Articles

Wish-Qol Study - Assessment of Health-Related Quality of Life (HRQoL) and Health-Economic Aspects in Patients with Von Willebrand Disease (VWD) in France: Results of the Women Cohort

Annie Borel-Derlon, MD PhD, Jenny Goudemand, MD PhD, Dominique Desprez, MD, Fabienne Volot, MD, Yves Gruel, MD, Sophie Bayard, MD, Catherine Chatelanaz, Catherine Doriat-Robin, Agnes Veyradier, MD PhD, Edith Fressinaud, MD, Sylvia von Mackensen, PhD

Blood (2016) 128 (22): 1395.

https://doi.org/10.1182/blood.V128.22.1395.1395

Published: 2016

Journal Articles

Beneficial Effect of Exogenous PF4 on SRA for Detecting Pathogenic HIT Antibodies

Caroline Vayne, Jérome Rollin, PhD, Eve Anne Guery, Claire Kizlik-Masson, Anne Bauters, Pharm D, Yves Gruel, MD, Claire Pouplard, Pharm D, PhD

Blood (2016) 128 (22): 3733.

https://doi.org/10.1182/blood.V128.22.3733.3733

Published: 2016

Journal Articles

Increased risk of thrombosis in FcγRIIA 131RR patients with HIT due to defective control of platelet activation by plasma IgG2

Jérôme Rollin, Claire Pouplard, Hsueh Cheng Sung, Dorothée Leroux, Armand Saada, Valérie Gouilleux-Gruart, Gilles Thibault, Yves Gruel

Blood (2015) 125 (15): 2397–2404.

https://doi.org/10.1182/blood-2014-09-594515

Published: 2015

Includes: Supplemental data

Journal Articles

Influence of FcγRIIA H131R Polymorphism on the Risk of Thrombosis in HIT and Variable Effect of Normal IgG on Platelet Activation

Jerôme Rollin, PhD, Claire Pouplard, Dorothee Leroux, Armand Saada, Céline Behier, Valérie Gouilleux Gruart, Gilles Thibault, PharmD, Yves Gruel, MD PhD

Blood (2014) 124 (21): 234.

https://doi.org/10.1182/blood.V124.21.234.234

Published: 2014

Journal Articles

Prospective Evaluation of a Rapid Nanoparticle-Based Lateral Flow Immunoassay (Stic Expert HIT ® ) for the Diagnosis of Heparin-Induced Thrombocytopenia

Claire Pouplard, PharmD, PhD, Dorothee Leroux, PharmD, Nathalie Hezard, MD, PhD, Aurelien Lebreton, MD, Anne Bauters, MD, William Cohen, Emmanuel De Maistre, MD, Isabelle Diaz, Pharm D, Marie-Genevieve Huisse, Catherine Ternisien, MD, Sophie Voisin, MD, Yves Gruel, MD, PhD

Blood (2012) 120 (21): 1087.

https://doi.org/10.1182/blood.V120.21.1087.1087

Published: 2012

Journal Articles

Polymorphisms of protein tyrosine phosphatase CD148 influence FcγRIIA-dependent platelet activation and the risk of heparin-induced thrombocytopenia

Jérôme Rollin, Claire Pouplard, Marie-Pierre Gratacap, Dorothée Leroux, Marc-Antoine May, Michel Aupart, Valérie Gouilleux-Gruart, Bernard Payrastre, Yves Gruel

Blood (2012) 120 (6): 1309–1316.

https://doi.org/10.1182/blood-2012-04-424044

Published: 2012

Includes: Supplemental data

Journal Articles

Incidence of Antibodies to Protamine/Heparin Complexes in Cardiac Surgery Patients and Impact on Platelet Activation in Vitro and Clinical Outcome

Claire Pouplard, PharmD, PhD, Dorothee Leroux, PharmD, Jerôme Rollin, PhD, Amiral Jean, PhD, May Marc Antoine, MD, Aupart Michel, MD, Yves Gruel, MD, PhD

Blood (2011) 118 (21): 2217.

https://doi.org/10.1182/blood.V118.21.2217.2217

Published: 2011

NARROW

Anti-Phospholipid Syndrome (APS) Antibody (Ab)-Induced Thrombosis Can be Blocked By Platelet Factor 4 (PF4)-Directed Abs: A Novel Therapeutic Approach for APS?

Heparin-PEAR1 Interaction Contributes to Platelet Activation By HIT Antibodies

ABO O blood group as a risk factor for platelet reactivity in heparin-induced thrombocytopenia

The Deglycosylated Form of 1E12, a Monoclonal Anti-PF4 IgG, Strongly Inhibits Antibody-Triggered Cellular Activation in Vaccine-Induced Thrombotic Thrombocytopenia, and Is a Potential New Treatment for Vιττ

Genome-Wide Association Study Identifies Variation in ABO As Risk Factor for Platelet Reactivity in Heparin-Induced Thrombocytopenia

Cleavage of anti-PF4/heparin IgG by a bacterial protease and potential benefit in heparin-induced thrombocytopenia

Fibronectin: a “double hit” modulator in HIT?

Is There an Alternative to Serotonin Release Assay for the Diagnosis of Heparin Induced Thrombocytopenia (HIT)? Evaluation of 5 Other Functional Methods Using 5B9 a Monoclonal IgG That Mimics HIT Human Antibodies

Cleavage of Anti-PF4/H IgG Antibodies By Ides, and Potential Benefit in the Treatment of Heparin-Induced Thrombocytopenia

Frequency of Anti-PF4/Heparin Antibodies in Patients Treated with Extra-Corporeal Membrane Oxygenation and Detection By Sensitized Serotonin Release Assay of Pathogenic Heparin-Induced Thrombocytopenia Antibodies

Gastrointestinal Bleeding and Angiodysplasia in Von Willebrand Disease: Results from the Ongoing French HRQoL Study: Wish-Qol

Inhibitor Development in Previously Untreated Patients with Severe Hemophilia a Treated with Nuwiq ® , a New Generation Recombinant FVIII of Human Origin

Characterization of 5B9, a Chimeric Monoclonal Anti-PF4/H Antibody with a Human Fc Fragment and Which Mimics the Effects of HIT Human Antibodies

Wish-Qol Study - Assessment of Health-Related Quality of Life (HRQoL) and Health-Economic Aspects in Patients with Von Willebrand Disease (VWD) in France: Results of the Women Cohort

Beneficial Effect of Exogenous PF4 on SRA for Detecting Pathogenic HIT Antibodies

Increased risk of thrombosis in FcγRIIA 131RR patients with HIT due to defective control of platelet activation by plasma IgG2

Influence of FcγRIIA H131R Polymorphism on the Risk of Thrombosis in HIT and Variable Effect of Normal IgG on Platelet Activation

Prospective Evaluation of a Rapid Nanoparticle-Based Lateral Flow Immunoassay (Stic Expert HIT ® ) for the Diagnosis of Heparin-Induced Thrombocytopenia

Polymorphisms of protein tyrosine phosphatase CD148 influence FcγRIIA-dependent platelet activation and the risk of heparin-induced thrombocytopenia

Incidence of Antibodies to Protamine/Heparin Complexes in Cardiac Surgery Patients and Impact on Platelet Activation in Vitro and Clinical Outcome

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only